# A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001)

> **NCT04055454** · PHASE1 · COMPLETED · sponsor: **Themis Bioscience GmbH** · enrollment: 60 (actual)

## Conditions studied

- Lassa Virus Infection

## Interventions

- **BIOLOGICAL:** MV-LASV
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04055454
- **Lead sponsor:** Themis Bioscience GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-26
- **Primary completion:** 2020-03-13
- **Final completion:** 2021-01-15
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-07-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04055454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04055454, "A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04055454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*